Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adalimumab in Crohn's disease (extension of M14-115)
2013-004034-15Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Endoscopic improvement at Week 40. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2013-004034-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004034-15.